Abstract
Our aim was to evaluate fatigue and quality of life (QoL) in Moroccan patients with primary Sjögren’s syndrome (PSS) and determine their correlates with disease-related parameters. Fifty-seven consecutive patients with PSS according to the American-European Consensus group (AEGG) criteria were included. Demographic, clinical, biological and immunological characteristics for all patients were collected. Xerostomia was demonstrated by histological grading of lower lip glandular biopsy. A Schirmer test was performed to measure lachrymal flow. Oral, ocular, skin, vaginal and tracheal dryness were evaluated by using a visual analogue scale (VAS). Fatigue was assessed by the Multidimensional assessment of fatigue (MAF) and the QoL by using the generic instrument: SF-36. 90% of our patients were women. The mean age of patients was 53.73 ± 7.69 years, and the mean disease duration was 5.38 ± 4.11 years. The mean oral dryness was 68.38 ± 20.29, and the mean ocular dryness was 51.91 ± 14.03. The mean total score of the MAF was 26.73 ± 8.33, and 87.5% of our patients experienced severe fatigue. Also, physical and mental domains of QoL were altered in a significant way, and the severity of fatigue had a negative impact on SF-36 scores. MAF and SF-36 scores were correlated with the delay of diagnosis, the intensity of xerostomia and the activity of joint involvement. A low socioeconomic and educational level had a negative impact on fatigue scores and QoL. Histological grading of lower lip glandular biopsy, immunological status and the severity of systemic involvement had no correlations with fatigue scores or the alteration of QoL. Patients receiving antidepressant have lesser fatigue and those receiving Methotrexate have better SF-36 scores. In our data, there was a high prevalence of fatigue in Moroccan patients with PSS associated with altered QoL. Severe fatigue and reduced QoL seem to be related to the severity of joint involvement, xerostomia and both educational and socioeconomic levels. Also, treatment with methotrexate and antidepressant seems to improve patients’ living and QoL. An appropriate therapeutic intervention for depression and articular manifestations in PSS should be applied to improve patients’ living.
Similar content being viewed by others
References
Carsons S (2001) A review and update of Sjögren’s syndrome: manifestations, diagnosis, and treatment. Am J Manag Care 7(14 Suppl):433–443
Segal B, Thomas W, Rogers T, Leon JM, Hughes P, Patel D, Patel K, Novitzke J, Rohrer M, Gopalakrishnan R, Myers S, Nazmul-Hossain A, Emamian E, Huang A, Rhodus N, Moser K (2008) Prevalence, severity, and predictors of fatigue in subjects with primary Sjögren’s syndrome. Arthritis Rheum 59(12):1780–1787
Fox RI (2005) Sjögren’s syndrome. Lancet 366(9482):321–331
Fox RI, Stern M, Michelson P (2000) Update in Sjögren syndrome. Curr Opin Rheumatol 12(5):391–398
Thomas E, Hay EM, Hajeer A, Silman AJ (1998) Sjögren’s syndrome: a community-based study of prevalence and impact. Br J Rheumatol 37(10):1069–1076
Oxholm P, Asmussen K (1995) Classification of disease manifestations in primary Sjögren’s syndrome: present status and a new proposal. Clin Rheumatol 14(Suppl 1):3–7
Tensing EK, Solovieva SA, Tervahartiala T, Nordström DC, Laine M, Niissalo S, Konttinen YT (2001) Fatigue and health profile in sicca syndrome of Sjögren’s and non-Sjögren’s syndrome origin. Clin Exp Rheumatol 19(3):313–316
Bowman SJ (2002) Collaborative research into outcome measures in Sjögren’s syndrome. Update on disease assessment. Scand J Rheumatol Suppl 116:23–27
Harboe E, Tjensvoll AB, Vefring HK, Gøransson LG, Kvaløy JT, Omdal R (2009) Fatigue in primary Sjögren’s syndrome–a link to sickness behaviour in animals? Brain Behav Immun 23(8):1104–1108
Segal B, Bowman SJ, Fox PC, Vivino FB, Murukutla N, Brodscholl J, Ogale S, McLean L (2009) Primary Sjögren’s Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 7:46
Bowman SJ (2008) Patient-reported outcomes including fatigue in primary Sjögren’s syndrome. Rheum Dis Clin North Am 34(4):949–962
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren’s Syndrome (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558
Neuberger GB (2003) Measures of fatigue. Arthritis Rheum 49:175–183
Bowman SJ, Booth DA, Platts RG, UK Sjögren’s Interest Group (2004) Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology (Oxford) 43(6):758–764
Khoudri I, Ali Zeggwagh A, Abidi K, Madani N (2007) Abouqal R Measurement properties of the short form 36 and health-related quality of life after intensive care in Morocco. Acta Anaesthesiol Scand 51(2):189–197
Strömbeck B, Theander E, Jacobsson LT (2005) Assessment of fatigue in primary Sjögren’s syndrome: the Swedish version of the Profile of Fatigue. Scand J Rheumatol 34(6):455–459
Lwin CT, Bishay M, Platts RG, Booth DA, Bowman SJ (2003) The assessment of fatigue in primary Sjögren’s syndrome. Scand J Rheumatol 32(1):33–37
Barendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, Markusse HM (1998) Fatigue in primary Sjögren’s syndrome. Ann Rheum Dis 57(5):291–295
Giles I, Isenberg D (2000) Fatigue in primary Sjögren’s syndrome: is there a link with the fibromyalgia syndrome? Ann Rheum Dis 59(11):875–878
Godaert GL, Hartkamp A, Geenen R, Garssen A, Kruize AA, Bijlsma JW, Derksen RH (2002) Fatigue in daily life in patients with primary Sjögren’s syndrome and systemic lupus erythematosus. Ann N Y Acad Sci 966:320–326
Smets EM, Garssen B, Bonke B, De Haes JC (1995) The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39:315–325
d’Elia HF, Rehnberg E, Kvist G, Ericsson A, Konttinen Y, Mannerkorpi K (2008) Fatigue and blood pressure in primary Sjogren’s syndrome. Scand J Rheumatol 37(4):284–292
Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P (2008) Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67(11):1541–1544
Calabrese LH, Davis ME, Wilke WS (1994) Chronic fatigue syndrome and a disorder resembling Sjögren’s syndrome: preliminary report. Clin Infect Dis 18(Suppl 1):28–31
Bax HI, Vriesendorp TM, Kallenberg CG, Kalk WW (2002) Fatigue and immune activity in Sjögren’s syndrome. Ann Rheum Dis 61(3):284
Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, Canavan A, Hamburger J, Richards A, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P, Rauz S, Bowman SJ (2008) The Sjögren’s Syndrome Damage Index—a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatology (Oxford) 47(8):1193–1198
Champey J, Corruble E, Gottenberg JE, Buhl C, Meyer T, Caudmont C, Bergé E, Pellet J, Hardy P, Mariette X (2006) Quality of life and psychological status in patients with primary Sjögren’s syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 55(3):451–457
Strömbeck B, Ekdahl C, Manthorpe R, Wikström I, Jacobsson L (2000) Health-related quality of life in primary Sjögren’s syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 29(1):20–28
Vriezekolk JE, Geenen R, Hartkamp A, Godaert GL, Bootsma H, Kruize AA, Bijlsma JW, Derksen RH (2005) Psychological and somatic predictors of perceived and measured ocular dryness of patients with primary Sjögren’s syndrome. J Rheumatol 32(12):2351–2355
Inal V, Kitapcioglu G, Karabulut G, Keser G, Kabasakal Y (2010) Evaluation of quality of life in relation to anxiety and depression in primary Sjögren’s syndrome. Mod Rheumatol [Epub ahead of print]
Kamel UF, Maddison P, Whitaker R (2009) Impact of primary Sjogren’s syndrome on smell and taste: effect on quality of life. Rheumatology (Oxford) 48(12):1512–1514
Meijer JM, Meiners PM, Huddleston Slater JJ, Spijkervet FK, Kallenberg CG, Vissink A, Bootsma H (2009) Health-related quality of life, employment and disability in patients with Sjogren’s syndrome. Rheumatology (Oxford) 48(9):1077–1082
Rostron J, Rogers S, Longman L, Kaney S, Field EA (2002) Health-related quality of life in patients with primary Sjögren’s syndrome and xerostomia: a comparative study. Gerodontology 19(1):53–59
Turan Y, Duruöz MT, Cerrahoglu L (2007) Quality of life in patients with ankylosing spondylitis: a pilot study. Rheumatol Int 27:895–899
Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W (2009) The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 7:25
Stewart CM, Berg KM, Cha S, Reeves WH (2008) Salivary dysfunction and quality of life in Sjögren syndrome: a critical oral-systemic connection. J Am Dent Assoc 139(3):291–299
Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, Lambert M, Launay D, Loustaud-Ratti V, Bezanahari H, Liozon E, Hachulla E, Jauberteau MO, Vidal E, Hatron PY (2010) Articular manifestations in primary Sjögren’s syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 49(6):1164–1172
Georges C, Chassany O, Mouthon L, Tiev K, Marjanovic Z, Meyer O, Toledano C, Ilie D, Guillevin L, Sereni D, Cabane J, Farge D (2004) Quality of life assessment with the MOS-SF36 in patients with systemic sclerosis. Rev Med Interne 25(1):16–21
Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL (2006) Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 45(7):885–889
Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B (2005) Leflunomide Rheumatoid Arthritis Investigators Groups, Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 32(4):590–601
Söderlin MK, Lindroth Y, Jacobsson LT (2007) Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology (Oxford) 46(8):1355–1358
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ibn Yacoub, Y., Rostom, S., Laatiris, A. et al. Primary Sjögren’s syndrome in Moroccan patients: characteristics, fatigue and quality of life. Rheumatol Int 32, 2637–2643 (2012). https://doi.org/10.1007/s00296-011-2009-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2009-5